News & Comments

Sarepta Announced Successful Results from a Preliminary Trial for Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) has news from preliminary Duchenne muscular dystrophy trials. Although the number of recruited patients was only three, the strong positive data excited the media and …

The FDA Approves Keytruda for Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL   - This is the 2nd indication for Keytruda for a hematologic malignancy. - The approval is based on tumor response rate …

AstraZeneca and Genentech Checkpoint Inhibitors Improve Survival in Two Different Lung Cancers

ASTRAZENECA AstraZeneca's (AZN) Checkpoint Inhibitor Imfinzi significantly improved Overall Survival (OS) for Stage III Non-Small Cell Cancer Imfinzi (durvalumab) achieved positive overall survival …

 

Today’s Highlights

Why FDA Approval of Agilent Technologies’ Assay is Important to Cervical Cancer Patients

The U.S. Food and Drug Administration (FDA) has approved Agilent Technologies’ (NYSE: A) Dako PD-L1 IHC 22C3 pharmDx assay for an expanded use. The …

CRISPR Editing and the Two Published Studies

Slashing of the CRISPR gene editing companies' stocks, including CRISPR Therapeutics (CRSP), Editas (EDIT) and Intellia (NTLA) is caused by two …

More Promising News for Array from Its Melanoma Combination Clinical Trial

Array BioPharma (ARRY) announced updated results from the Phase 3 COLUMBUS trial in BRAF-mutant advanced melanoma. The results showed that the …

About Nektar’s Product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was …

Recent Popular Posts:

Sarepta Announced Successful Results from a Preliminary Trial for Duchenne Muscular Dystrophy

Sarepta Therapeutics (SRPT) has news from preliminary Duchenne muscular dystrophy trials. Although the number of recruited patients was only three, the strong positive data excited the media and Wall Street investors …

Good News, Bad News and Comebacks. Some ASCO Results Too

The Week in Review

Top